Starpharma Holdings base_Schulden 2024

Starpharma Holdings base_Schulden

−26,91 AUD

Starpharma Holdings components_Profile_KeyStats__24

components_StockPageHeader__3

SPL.AX

components_StockPageHeader__4

AU000000SPL0

components_StockPageHeader__5

796461

pages_kennzahlen_[key]_[isin]__42

Starpharma Holdings Aktienanalyse

pages_kennzahlen_[key]_[isin]__1

Starpharma Holdings Ltd is an Australian company specializing in the development of innovative solutions in the fields of pharmacy and biotechnology. The company was founded in 1996 and has since written an impressive history full of successful developments and numerous partnerships. The main business of Starpharma focuses on the development and commercialization of drugs and other health products based on dendrimer technology. One of the most advanced applications of dendrimer technology is VivaGel, a topical gel for the prevention of sexually transmitted diseases, particularly HPV (Human Papillomavirus). VivaGel is based on a dendrimer that acts both as an antiviral agent and an antibiotic, capable of preventing infection by different types of HPV. The product has already undergone Phase III clinical trials and is currently being marketed worldwide. In addition to VivaGel, Starpharma also offers dendrimer-based technologies and services in the field of drug development. The company has formed numerous partnerships with major pharmaceutical companies such as AstraZeneca, GSK, and Merck, and is involved in the development of drugs for cancer, autoimmune diseases, and infectious diseases. Furthermore, Starpharma has expanded its dendrimer technology to other industries, such as agriculture, where dendrimers can contribute to improving soil quality and reducing pesticide use. In this sector, Starpharma has also formed partnerships with agricultural companies such as Adama and Nufarm. Overall, Starpharma is a company that has experienced significant growth in recent years and continues to focus on the development of new and innovative products and solutions. Its core competence in dendrimer technology has allowed it to establish itself as a key player in various industries and build numerous partnerships with global companies. With its diverse range of products and services and a strong focus on research and development, Starpharma can be considered an important player in the field of biotechnology and healthcare innovations. Indicate the sector in starpharma specialize in. Starpharma Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

pages_kennzahlen_[key]_[isin]__85

pages_kennzahlen_[key]_[isin]__78

pages_dividenden_[isin]_index__2

components_kpi_DebtFaqs_0

components_kpi_DebtFaqs_1

components_kpi_DebtFaqs_2

components_kpi_DebtFaqs_3

components_kpi_DebtFaqs_4

components_kpi_DebtFaqs_5

components_kpi_DebtFaqs_6

components_kpi_DebtFaqs_7

components_kpi_DebtFaqs_8

components_kpi_DebtFaqs_9

components_kpi_DebtFaqs_10

components_kpi_DebtFaqs_11

components_kpi_DebtFaqs_12

components_kpi_DebtFaqs_13

components_kpi_DebtFaqs_14

components_kpi_DebtFaqs_15

components_kpi_DebtFaqs_16

components_kpi_DebtFaqs_17

pages_aktie_[isin]_[key]_index_0

pages_aktie_[isin]_[key]_index_1

pages_aktie_[isin]_[key]_index_2

pages_aktie_[isin]_[key]_index_3

pages_aktie_[isin]_[key]_index_4

pages_aktie_[isin]_[key]_index_5

pages_aktie_[isin]_[key]_index_6

pages_aktie_[isin]_[key]_index_7

pages_aktie_[isin]_[key]_index_8

pages_aktie_[isin]_[key]_index_9

pages_aktie_[isin]_[key]_index_10

pages_aktie_[isin]_[key]_index_14

Wann musste ich die Aktien von Starpharma Holdings kaufen, um die vorherige Dividende zu erhalten?

pages_aktie_[isin]_[key]_index_15

pages_aktie_[isin]_[key]_index_16

pages_aktie_[isin]_[key]_index_18

pages_aktie_[isin]_[key]_index_19

pages_aktie_[isin]_[key]_index_20

pages_aktie_[isin]_[key]_index_21

pages_aktie_[isin]_[key]_index_22

components_kpi_Savingsplan_0